🇺🇸 PMV Pharmaceuticals, Inc.PMVP

Company Update Form 8-K 20-11-2026 16:05:13 EST

Subject: 8-K Items 8.01, 9.01

Overview: Announced updated Phase 2 PYNNACLE trial data for rezatapopt, reporting a 48% ORR in ovarian cancer patients and planned NDA submission in Q1 2027.

Source: SEC EDGAR · Original filing

Open document in a new tab

Get filings like this in Telegram the moment they are published — for the companies you follow.

Start 30-day trial About Finterest